(Q39890236)

15 September 2017

title

Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity (English)

1 reference

15 September 2017

0 references

1 reference

Lysann Schädlich

1

1 reference

15 September 2017

Tilo Senger

2

1 reference

15 September 2017

Carsten J Kirschning

3

1 reference

15 September 2017

Martin Müller

4

1 reference

15 September 2017

Lutz Gissmann

5

1 reference

15 September 2017

language of work or name

English

0 references

publication date

25 January 2009

1 reference

15 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

15 September 2017

volume

27

1 reference

15 September 2017

issue

10

1 reference

15 September 2017

page(s)

1511-1522

1 reference

Chapter 2: The burden of HPV-related cancers

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Introducing HPV vaccine in developing countries--key challenges and issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Endotoxin removal from protein solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Inflammatory Effects of Endotoxin-Like Contaminants in Commonly Used Protein Preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

New hepatitis B vaccine formulated with an improved adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Human papillomavirus infection requires cell surface heparan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Further evidence that papillomavirus capsids exist in two distinct conformations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Removal of endotoxin from protein solutions by phase separation using Triton X-114

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Removal of endotoxin from recombinant protein preparations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Heat shock proteins transfer peptides during antigen processing and CTL priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Structure and function of lipopolysaccharides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Initial responses to endotoxins and Gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

Papillomavirus capsid binding and uptake by cells from different tissues and species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.01.014

1 reference

15 September 2017

1 reference